Quel est le prix pour Healios K.K. (4593)

Le prix pour Healios K.K. (4593) est $1.89

Quelle est la capitalisation boursière pour Healios K.K. (4593)

La capitalisation boursière pour Healios K.K. (4593) est $254.55M

Healios K.K. (4593) Marge Opérationnelle

Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.

Année	Marge opérationnelle	Changez
Pas assez de données pour les dates fournies.

Année

Marge opérationnelle

Changez

Pas assez de données pour les dates fournies.

Entreprise	Marge opérationnelle	Différence de Marge Opérationnelle	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.57%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH

Entreprise

Marge opérationnelle

Différence de Marge Opérationnelle

Pays